Follicular Lymphoma
The latest news, research, and perspectives in follicular lymphoma (FL).
Advertisement
Tumor cells in high-risk follicular lymphoma had enhanced B-cell receptor signaling and distinct follicular growth patterns.
The approval was declined due to the enrollment status of the confirmatory trials.
Common adverse reactions to zanubrutinib observed across studies included decreased neutrophil and platelet counts.
The multicenter, single-arm phase II trial evaluated axicabtagene ciloleucel in patients with MZL or follicular lymphoma.
Axi-cel yielded improved long-term outcomes versus conventional treatments in extended follow-up of the ZUMA-5 trial.
At a median follow-up of 18.1 months, the ORR and CR rates were both 95.7% following liso-cel treatment.
Advertisement
In episode four of the 2024 season, Dr. Coombs shares updates in CHIP from ASH 2023.
Liso-cel received regulatory acceptances from the US FDA and the Ministry of Health, Labour and Welfare in Japan for FL.
The agency's statement follows potential risks identified by the FDA Adverse Event Reporting System.
Epcoritamab yielded deep responses with promising response rates in high-risk relapsed or refractory follicular lymphoma.
The trial studied a fixed-duration regimen of mosunetuzumab plus lenalidomide in follicular lymphoma.
Among 26 response-evaluable patients, the best overall response rate was 96% and the complete response rate was 81%.
The abstract investigators presented data from the phase II TRANSCEND FL trial.
Pirtobrutinib showed potential efficacy among patients with relapsed or refractory follicular lymphoma.
Dr. Dickinson joins "Blood Cancer Talks" hosts to discuss phase I and II trials on DLBCL, follicular lymphoma, and more.
The Committee for Medicinal Products for Human Use of the European Medicines Agency supported approving zanubrutinib for FL.
The findings "may contribute to future improved risk assessment and personalized management strategies for patients."
Dr. Nastoupil spoke about how the meeting can help clinicians learn how apply knowledge from the latest research.
September is Leukemia and Lymphoma Awareness Month, with Lymphoma Awareness Day marked on September 15.
The phase II study evaluated liso-cel in patients with relapsed or refractory follicular lymphoma.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.